{
  "docId": "019de075-242a-7291-8f16-5f142d7cb798",
  "docSlug": "c8e6c54234adac3c3fb2311a09419808",
  "documentTitle": "Freeman Capital Management | Activist Presentation Deck | 15 slides",
  "authorId": "freeman-capital-management",
  "authorName": "Freeman Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 15,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline structure to contrast Dr. Freeman's actions with the company's narrative and board actions.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-242a-7291-8f16-5f142d7cb798/14",
  "deckHref": "/decks/019de075-242a-7291-8f16-5f142d7cb798",
  "deckJsonHref": "/decks/019de075-242a-7291-8f16-5f142d7cb798.json",
  "deckAnchorHref": "/decks/019de075-242a-7291-8f16-5f142d7cb798#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.39,
        "y": 0.418
      },
      "kind": "callout",
      "text": "Dr. Freeman is suspended from his duties as CMO (he subsequently left the Company in August 2020): Ms. Brigid Makes, a current board member, served as the Head of HR at the time.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e23604c-4909-40cd-831e-e492ea524dae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.33,
        "x": 0.06,
        "y": 0.418
      },
      "kind": "callout",
      "text": "Dr. Freeman halted the Phase I study at 8mg due to safety concerns – humans were more sensitive to MM-110 than indicated by previous pre-clinical studies.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a05578b1-b212-4d70-bc77-f291f6ef9121",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.92,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Timeline of events from 2015 to August 2022",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c756af30-0033-4729-a4d5-00908d177f57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: MindMed Press Releases, Company's SEC Filing, Clinicaltrials.gov.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "363840e8-7663-42ac-8334-4f46acc22e15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.5,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "Dr. Freeman Halts MM-110 Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "701e4688-540d-4d28-a592-359d3c7332be",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "expose_contradiction",
      "slug": null,
      "matchId": "483580ef-cbbd-446c-af16-7c090eb768f1",
      "evidence": "Contrasting the safety-based halt by Dr. Freeman with the board's punitive response.",
      "confidence": 0.9
    },
    {
      "name": "timeline",
      "slug": null,
      "matchId": "47775642-a020-4146-ae59-fec9151d1565",
      "evidence": "Chronological sequence of events presented across the slide.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 13,
      "beatId": "64d1132b-b638-45d0-85c8-3bf96678b675",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Struggle (Freeman Capital Management's efforts)",
      "beatSlug": "overcoming-monster-the-struggle",
      "evidence": "Slides 13-14 present Dr. Freeman's actions and the conclusion.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 13,
      "name": "The Reveal",
      "slug": "05-the-reveal",
      "bestFor": "Product launches, strategic pivots, unexpected findings",
      "matchId": "d42f7ac4-dd89-40b9-860d-e7cfdbbe2b7b",
      "evidence": "Slides 13-15 present Dr. Freeman's actions and the conclusion.",
      "position": 0,
      "objective": "Reveal Freeman Capital Management's solution and call to action",
      "structure": "Setup the Question -> Build Suspense -> The Big Reveal",
      "confidence": 0.7,
      "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}